[go: up one dir, main page]

WO2011073905A8 - Novel tumor markers - Google Patents

Novel tumor markers Download PDF

Info

Publication number
WO2011073905A8
WO2011073905A8 PCT/IB2010/055805 IB2010055805W WO2011073905A8 WO 2011073905 A8 WO2011073905 A8 WO 2011073905A8 IB 2010055805 W IB2010055805 W IB 2010055805W WO 2011073905 A8 WO2011073905 A8 WO 2011073905A8
Authority
WO
WIPO (PCT)
Prior art keywords
stage
progressed
cancer
tumor markers
progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/055805
Other languages
French (fr)
Other versions
WO2011073905A1 (en
Inventor
Ralf Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips Electronics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09179125A external-priority patent/EP2295977A1/en
Application filed by Koninklijke Philips Electronics NV filed Critical Koninklijke Philips Electronics NV
Priority claimed from PCT/IB2010/055796 external-priority patent/WO2011073896A1/en
Publication of WO2011073905A1 publication Critical patent/WO2011073905A1/en
Publication of WO2011073905A8 publication Critical patent/WO2011073905A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a tumor marker or group of tumor markers associated with the progression of a cancer disease from a less progressed stage to a more progressed stage, wherein the expression of the tumor markers is modified when comparing the expression in the less progressed stage and in the more progressed stage. The present invention further relates to a composition for diagnosing, detecting, graduating, monitoring or prognosticating a cancer disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage comprising affinity ligands for the expression products of the tumor markers, to corresponding methods, and to the use of said tumor markers for detecting, diagnosing,graduating, monitoring or prognosticating a cancer disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage. The present invention further relates to a corresponding immunoassay, to a method of identifying an individual for eligibility for a cancer disease therapy, as well as to a pharmaceutical composition based on the inhibition of the expression of said tumor markers. The present invention further relates to a corresponding immunoassay for stratifying a patient or cohort of patients with a cancer disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage to a therapeutic treatment for monitoring a therapeutic treatment of the stratified patient(s) during the progression from a less progressed cancer stage to a more progressed cancer stage.
PCT/IB2010/055805 2009-12-14 2010-12-14 Novel tumor markers Ceased WO2011073905A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP09179125.1 2009-12-14
EP09179125A EP2295977A1 (en) 2009-09-03 2009-12-14 Novel tumor markers
EP10155369 2010-03-03
EP10155369.1 2010-03-03
EP10165039 2010-06-07
EP10165039.8 2010-06-07
IBPCT/IB2010/055796 2010-12-14
PCT/IB2010/055796 WO2011073896A1 (en) 2009-12-14 2010-12-14 Novel tumor markers

Publications (2)

Publication Number Publication Date
WO2011073905A1 WO2011073905A1 (en) 2011-06-23
WO2011073905A8 true WO2011073905A8 (en) 2011-12-08

Family

ID=44246840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/055805 Ceased WO2011073905A1 (en) 2009-12-14 2010-12-14 Novel tumor markers

Country Status (1)

Country Link
WO (1) WO2011073905A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014028659A2 (en) 2012-06-07 2017-07-25 Hoffmann La Roche cancer diagnostic methods, erlotinib, uses of an autoantibody, kits and invention
US10739346B2 (en) 2014-02-04 2020-08-11 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against EGF-receptor
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
WO2019139754A2 (en) * 2017-12-19 2019-07-18 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for fetal growth

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090580A1 (en) * 2001-05-03 2002-11-14 National Cancer Centre Of Singapore Pte Ltd Identifying liver cancer by detecting aberrant expression of insulin like growth factor binding protein
JP2006514554A (en) * 2002-11-21 2006-05-11 ワイス Diagnosis of renal cell carcinoma and other solid tumors
US20040253606A1 (en) * 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators

Also Published As

Publication number Publication date
WO2011073905A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
WO2011027310A8 (en) Novel tumor markers
WO2006036220A3 (en) Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008079269A3 (en) Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
WO2007140958A3 (en) Method for identifying whether a patient will be responder or not to immunotherapy
CY1118566T1 (en) DIAGNOSIS USING INTERFERENCE TYPE 1
WO2009037454A3 (en) Cancer marker and therapeutic target
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008072777A3 (en) Ttk as tumor marker and therapeutic target for lung cancer
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
EP4435112A3 (en) Compositions and methods for screening solid tumors
WO2013096903A3 (en) Methods for prediction of clinical response to radiation therapy in cancer patients
BR112013008573A2 (en) biomarker cytokines as indicators of clinical response to glatiramer acetate.
WO2012044696A3 (en) Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature
WO2011073905A8 (en) Novel tumor markers
MX2013006361A (en) Agtr1 as a marker for bevacizumab combination therapies.
SG179129A1 (en) Method for identifying whether a patient will be responder or not to immunotherapy
WO2011027311A3 (en) Novel tumor markers
WO2010131193A8 (en) Phosphodiesterase 9a as prostate cancer marker
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
Bae et al. Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B–2B cervical cancer
WO2011051271A3 (en) Prostate tumor markers and methods of use thereof
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
JP2012524248A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10809189

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10809189

Country of ref document: EP

Kind code of ref document: A1